Genetic evidence for associations between gastroesophageal reflux disease and site-specific extraesophageal cancers: A Mendelian randomization study.

Medicine (Baltimore)Oct 2, 2026
Clinical ResearchGastroenterologyOncology (Medical)Medical Genetics

Siyu Wang, Menglin Guo, Siyu Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This Mendelian randomization study investigated the relationship between genetically predicted gastroesophageal reflux disease (GERD) and 22 extraesophageal cancers using data from over 600,000 individuals. The analysis revealed a significant association between GERD and lung cancer (OR = 1.220) and pancreatic cancer (OR = 1.517), while associations with laryngeal and bladder cancers were suggestive but not statistically significant after correction.

Key findings

  • Genetically predicted GERD was associated with lung cancer (OR = 1.220; P = .0002).
  • A significant association was found between GERD and pancreatic cancer (OR = 1.517; P = .0002).
  • Laryngeal cancer showed a suggestive association with GERD (OR = 1.774; P = .021).
  • The association with lung cancer remained significant after adjusting for body mass index, smoking, and alcohol consumption (OR = 1.190; P = .012).

Why it matters

Understanding the genetic links between GERD and specific cancers can inform clinicians about potential cancer risks in patients with GERD, guiding surveillance and management strategies. This research highlights the need for further investigation into these associations.

Source

PubMed · PMID 42826299

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.